Teva: Avoid

Source: Tradingview

Investment Thesis

Teva Pharmaceutical (TEVA) recently announced that it has entered into a definitive agreement to sell its Paragard contraceptive device to CooperSurgical for $1.1 billion (this transaction is expected to close before the end of 2017). The company is reversing its previous strategy of acquisition-based growth so as to reduce its massive debt load of about $35 billion. While the company faces very intense competition in the generic segment and struggles to pay off its debt, the stock will continue to face selling pressure.

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.